Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Thank you for attending our Global Healthcare Conference. Today, I have the pleasure to host Joe Romanelli, President of Human Health International; and Peter Dannenbaum, Head of Investor Relations.

(Reuters) -Daiichi Sankyo and Merck said on Tuesday that their drug ... plan to present data from the trial at an upcoming medical meeting and share it with global regulatory authorities to discuss ...

Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared ...

Under a MOU signed between both the parties, Merck and Siemens have decided to expand their cooperation in Smartfacturing.

Merck (NYSE:MRK) and Daiichi Sankyo (OTCPK:DSNKY) announced Tuesday that their jointly developed lung cancer drug patritumab ...

Merck and Daiichi Sankyo said a Phase 3 study evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who received prior EGFR tyrosine ...

Lack of a skilled talent pool, and slow logistics operations are among the major challenges that could discourage India’s ...

Nestled in verdant greenery, the innovation hub’s like-minded community, customisable workspaces and proximity to key ...

Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...